Evidence map›Paper›PMID 32780341›Full record

ReviewNetherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation2020

The role of long-term mechanical circulatory support in patients with advanced heart failure.

S E A Felix, N de Jonge, K Caliskan, O Birim, K Damman, M Kuijpers, L F Tops, M Palmen, F Z Ramjankhan

Open access · diamondAbstract readReview
In one paragraph

Review in Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
  4. Left ventricular assist device implantation and clinical outcomes in the Netherlands.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2023
    Article
  5. Hyperpolypharmacy is a predictor of mortality after left ventricular assist device (LVAD) implantation.American heart journal plus : cardiology research and practice · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

S E A FelixDepartment of Cardiology, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands. s.e.a.felix@umcutrecht.nl.
N de JongeDepartment of Cardiology, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
K CaliskanDepartment of Cardiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
O BirimDepartment of Cardiothoracic Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
K DammanDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
M KuijpersDepartment of Cardiothoracic Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
L F TopsDepartment of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
M PalmenDepartment of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, The Netherlands.
F Z RamjankhanDepartment of Cardiothoracic Surgery, University Medical Center of Utrecht, University of Utrecht, Utrecht, The Netherlands.
Utrecht University · NLErasmus MC · NLLeiden University Medical Center · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In patients with end-stage heart failure, advanced therapies such as heart transplantation and long-term mechanical circulatory support (MCS) with a left ventricular assist device (LVAD) have to be considered. LVADs can be implanted as a bridge to transplantation or as an alternative to heart transplantation: destination therapy. In the Netherlands, long-term LVAD therapy is gaining importance as a result of increased prevalence of heart failure together with a low number of heart transplantations due to shortage of donor hearts. As a result, the difference between bridge to transplantation and destination therapy is becoming more artificial since, at present, most patients initially implanted as bridge to transplantation end up receiving extended LVAD therapy. Following LVAD implantation, survival after 1, 2 and 3 years is 83%, 76% and 70%, respectively. Quality of life improves substantially despite important adverse events such as device-related infection, stroke, major bleeding and right heart failure. Early referral of potential candidates for long-term MCS is of utmost importance and positively influences outcome. In this review, an overview of the indications, contraindications, patient selection, clinical outcome and optimal time of referral for long-term MCS is given.

Indexed as

Advanced heart failureAdverse eventsLeft ventricular assist deviceSurvival

Identifiers

PMID32780341
PMCPMC7419399
OpenAlexW3048790167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.